Philips HealthCare parent company Royal Philips is highlighting that the company-coordinated Imagio consortium was recently awarded an Innovative Health Initiative grant worth 24 million euros.
The grant will support the consortium's research efforts for less invasive cancer treatments, which focus on lung cancer, liver cancer, and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud, and Utrecht University Medical Centers in the Netherlands, and University Hospital of Cologne in Germany.
The following are projects being undertaken by the consortium:
- Collaboration with Radboud University Medical Center and other partners to further expand diagnosis and minimally invasive treatment of lung cancer supported by Philips' Azurion image-guided therapy platform.
- Collaboration with Leiden and Maastricht University Medical Centers to improve the diagnosis and treatment of liver cancer using CT, ultrasound, precision marking, and ablation technology.
- Collaboration with University Medical Center Utrecht and TU Delft to improve the treatment of liver cancer through radioembolization supported by hybrid imaging modalities.
- Collaboration between University Hospital of Cologne, Profound Medical and Philips to treat soft tissue sarcomas with MR-guided high-intensity focused ultrasound in combination with Thermosome's lead drug candidate THE001.
